abstract |
The present invention is directed to compounds of formula (A), pharmaceutical compositions, and methods of use for treating macular degeneration, reducing its symptoms, or reducing its risk. For example, the invention treats macular degeneration and other retinal diseases or disorders caused by accumulation of A2E and / or lipofuscin in retinal tissue or by VEGF signaling by RPE cells in response to oxidative stress, The present invention relates to compounds, pharmaceutical compositions, and methods for reducing the symptoms of or reducing the risk of developing them. |